US President Barack Obama has ordered the Food and Drug Administration (FDA) to remedy the problem of drug shortages in the country.

Over the past year, the majority of hospitals in the US have been forced to delay life-saving treatments due to the shortages, which tend to affect cancer drugs and anaesthetics.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

So far, at least 15 deaths have been blamed on the lack of medicines.

Obama signed the executive order on Monday instructing the FDA to take action to broaden its reporting of potential drug shortages, accelerate reviews of applications to change production of drugs facing potential shortages and give the Justice Department more information about possible instances of collusion or price gouging.

However, the administration said the steps won’t solve the problem as shortages have tripled in recent years and show no signs of slowing, reports the Associated Press.

Around 178 shortages reported last year, and shortages of injectable drugs are becoming increasingly apparent, according to the FDA.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The FDA won’t "be able to prevent all future shortages," said Commissioner Margaret Hamburg. "But we can make a very real and meaningful difference by expanding our network of early warnings."

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact